BackgroundCheck.run
Search For

Martin J Corbett, 671 W Hoffman Ave, Cherry Hill, NJ 08002

Martin Corbett Phones & Addresses

Merchantville, NJ   

Cherry Hill, NJ   

Glassboro, NJ   

Maple Shade, NJ   

Old Bridge, NJ   

2 S Cove Rd, Merchantville, NJ 08109   

Mentions for Martin J Corbett

Martin Corbett resumes & CV records

Resumes

Martin Corbett Photo 29

Director Of Property Management Purchasing

Location:
Merchantville, NJ
Industry:
Automotive
Work:
Pep Boys
Director of Property Management Purchasing
Avellinos Sep 1993 - Jun 1999
District Manager
Auto Depot Giant Aug 1990 - Sep 1993
Director of Service Operations
The Goodyear Tire & Rubber Company Jul 1984 - Aug 1990
District Manager
Pep Boys Jun 1976 - Apr 1984
Automotive Technician - Service Manager
Corbett's Automotive 1968 - Jun 1976
Automotive Technician
Skills:
Ase Master Technician, Cpm Certified
Martin Corbett Photo 30

Martin Corbett

Martin Corbett Photo 31

Martin Corbett

Location:
United States
Martin Corbett Photo 32

Martin Corbett

Location:
United States

Publications & IP owners

Us Patents

Headset/Groundcord Tester Apparatus

US Patent:
4356356, Oct 26, 1982
Filed:
Sep 18, 1980
Appl. No.:
6/188411
Inventors:
Martin E. Corbett - New York NY
International Classification:
H04M 322
H04R 2900
US Classification:
1791751R
Abstract:
A test set for checking headsets and groundcords utilizing an internally generated electrical signal to determine the state of individual wires by means of a visual indication. The headset is powered by the test set to enable the test set operator to speak into the headset microphone and hear the results in the earpiece.

Receptors Method For Purification Of G Protein-Linked

US Patent:
5225543, Jul 6, 1993
Filed:
Mar 28, 1991
Appl. No.:
7/677003
Inventors:
Cecil M. Eppler - Langhorne PA
Hong-Ming Shieh - Langhorne PA
John R. Zysk - Frenchtown NJ
Martin J. Corbett - Pemberton NJ
Assignee:
American Cyanamid Company - Wayne NJ
International Classification:
C07K 320
C07K 312
C07K 318
C07K 328
US Classification:
530413
Abstract:
The receptor:ligand complex is applied to a solid phase substrate which binds the complex by specifically binding the ligand. The receptor is dissociated from the substrate bound receptor:ligand complex with an eluant capable of releasing the receptor from the ligand and leaving the ligand bound to the solid phase substrate. GTP containing eluants are effective. The receptor is recovered from the eluate and optionally subjected to further purification.

Human Fc-Bearing Igg Antibodies To Polyethylene Glycol

US Patent:
2018003, Feb 8, 2018
Filed:
Sep 29, 2017
Appl. No.:
15/720073
Inventors:
- Princeton NJ, US
Alexander T. Kozhich - Princeton NJ, US
Martin J. Corbett - Mount Holly NJ, US
Zheng Lin - North Wales PA, US
Steven P. Piccoli - Princeton NJ, US
International Classification:
G01N 33/68
C07K 16/44
Abstract:
Polyethylene glycol (PEG) is often conjugated with therapeutic proteins to enhance their PK properties. PEG may, however, be immunogenic, and the presence of PEG in food and cosmetics is believed to result in pre-existing anti-PEG antibodies in humans. Polyclonal and monoclonal antibodies reactive to PEG are provided for use in immunogenicity assay development to detect such anti-drug antibodies. Such antibodies exhibit preferential binding based on the size of PEG with molecular weight ranging from 350 daltons to 40 kD. Anti-PEG antibodies of the invention are engineered to comprise human Fc regions to enable non-bridging immunoassay formats.

Human Fc-Bearing Igg Antibodies To Polyethylene Glycol

US Patent:
2016023, Aug 11, 2016
Filed:
Feb 8, 2016
Appl. No.:
15/018353
Inventors:
- Princeton NJ, US
Alexander T. Kozhich - Princeton NJ, US
Martin J. Corbett - Mount Holly NJ, US
Zheng Lin - North Wales PA, US
Steven P. Piccoli - Princeton NJ, US
International Classification:
G01N 33/68
C07K 16/44
Abstract:
Polyethylene glycol (PEG) is often conjugated with therapeutic proteins to enhance their PK properties. PEG may, however, be immunogenic, and the presence of PEG in food and cosmetics is believed to result in pre-existing anti-PEG antibodies in humans. Polyclonal and monoclonal antibodies reactive to PEG are provided for use in immunogenicity assay development to detect such anti-drug antibodies. Such antibodies exhibit preferential binding based on the size of PEG with molecular weight ranging from 350 daltons to 40 kD. Anti-PEG antibodies of the invention are engineered to comprise human Fc regions to enable non-bridging immunoassay formats.

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.